NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) CEO Joel Becker bought 11,891 shares of the company’s stock in a transaction on Tuesday, November 17th. The shares were bought at an average price of $8.35 per share, for a total transaction of $99,289.85. Following the transaction, the chief executive officer owned 149,891 shares of the company’s stock, valued at approximately $1,251,589.85. This represents a 8.62% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
NeuroPace Price Performance
NeuroPace stock opened at $8.20 on Wednesday. NeuroPace, Inc. has a one year low of $5.46 and a one year high of $19.60. The business has a fifty day moving average price of $12.94 and a 200-day moving average price of $14.67. The company has a debt-to-equity ratio of 5.15, a current ratio of 5.26 and a quick ratio of 4.09. The firm has a market capitalization of $282.49 million, a P/E ratio of -14.64 and a beta of 1.98.
Analysts Set New Price Targets
NPCE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reduced their target price on NeuroPace from $21.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, November 13th. Wells Fargo & Company cut NeuroPace from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $19.00 to $9.00 in a research report on Friday, November 13th. Wall Street Zen downgraded shares of NeuroPace from a “hold” rating to a “sell” rating in a report on Saturday. Mizuho cut their price objective on shares of NeuroPace from $22.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Wolfe Research lowered shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Monday. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.11.
Latest NeuroPace News
Here’s some of the latest news about NPCE:
- Negative Sentiment: Wolfe Research downgraded NPCE from “strong buy” to “hold,” while Wall Street Zen cut its rating to “sell.” These changes add to pressure on investor sentiment. Wall Street Zen rating report
- Negative Sentiment: Recent coverage cites a third-quarter miss, weak implant activity and execution and regulatory risks. HC Wainwright and Cantor Fitzgerald lowered their price targets to $12, although both retained bullish ratings. Zacks analysis
- Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to NeuroPace raising its 2026 revenue outlook in August and then lowering it to $91–$92 million the following quarter. The announcement creates legal and reputational uncertainty. Investigation notice
Institutional Investors Weigh In On NeuroPace
A number of large investors have recently added to or reduced their stakes in NPCE. BlackRock Inc. purchased a new position in shares of NeuroPace during the 2nd quarter valued at about $39,369,000. First Light Asset Management LLC lifted its position in NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock worth $32,349,000 after buying an additional 1,110,484 shares during the last quarter. Deutsche Bank AG bought a new stake in NeuroPace in the 2nd quarter worth approximately $14,919,000. Soleus Capital Management L.P. lifted its position in NeuroPace by 10.5% in the 3rd quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company’s stock worth $44,280,000 after buying an additional 306,878 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in NeuroPace in the second quarter worth approximately $1,836,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
- Five stocks we like better than NeuroPace
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
